Cystic Fibrosis Clinical Trial
Official title:
Do Physiotherapy Joint and Muscle Movement (Musculoskeletal) Techniques Improve Posture, Pain, Sputum Clearance, Lung Function or Quality of Life During Admission for a Respiratory Exacerbation in Adults With Cystic Fibrosis?
Hypothesis: The addition of a series of musculoskeletal techniques to normal optimal care for the treatment of a respiratory exacerbation in inpatient adults with cystic fibrosis, will lead to further improvements in pain, posture, sputum clearance, lung function and quality of life.
Experimental design
A prospective, single blind, randomised control trial.
Methods
50 subjects will be recruited by the admitting physiotherapists from the inpatient wards at
Royal Brompton Hospital. Using stratified computer randomisation, the subjects will be
allocated to either the control (no treatment group) or the treatment group. The
randomisation will be carried out by an independent member of the Department of Cystic
Fibrosis and the outcome measures recorded by an observer blind to the randomisation.
Method:
- Two key investigators will be involved in the study to perform the treatment
intervention as outlined in the paragraphs below
- The subjects' records will be reviewed by the key investigators to ensure they meet the
inclusion criteria
- Prospective subjects will be given written and verbal information about the project and
be given 24 hours to consider entry to the study
- Subjects will give written consent to participate in the project. The top copy will be
included in the patient's medical record and a copy placed in the patient's study file
- A letter will be written to the subject's General Practitioner outlining the purpose of
the study and inviting him/her to make contact to discuss the study in more detail if
there are any queries or concerns
- The subjects will be withdrawn if there is a clinical deterioration negating the
inclusion criteria or they are discharged for further home intravenous antibiotic
treatment
- Three independent observers (the senior & junior physiotherapists usually working with
this patient group) will be trained to ensure good intra & inter-relater reliability in
the recording of the measurements
Intervention for the treatment group:
The treatment group will receive the interventions on top of their usual chest physiotherapy
and medical care. A treatment series of gentle joint and muscle movements (musculoskeletal
interventions) will be undertaken by a physiotherapist, on alternate days for the duration
of admission. The physiotherapy musculoskeletal assessment and intervention may last up to
45 minutes on alternate weekdays and may include one or a combination of the following
techniques which are documented in populations with postural changes, thoracic stiffness,
discomfort and/or pain:
- Specific, gentle oscillatory mobilisations to the rib cage and thoracic spine of the
subjects to improve joint alignment and mobility, and to reduce pain. These techniques
should optimise chest wall mechanics, improve the length-tension relationships of the
muscles and normalise movement to dysfunctional areas (Maitland, Banks et al.
2001;Mulligan 2005)
- Treatment of specific muscle dysfunction or tight muscle groups to further optimise
muscle length and biomechanical relationships in the area (Massery 2005), leading to
improved efficiency of recruitment and improved power output (Travell & Simons 1983)
- Postural education and awareness discussions to improve the subject's own joint
alignment and ability in a functional manner. A short programme to reinforce the
progress during the treatment sessions consisting of no more than three specific
stretching or strengthening exercises may be given.
Control Group:
The control group will receive their usual medical and physiotherapy management but no
placebo intervention.
Data Collection:
The outcome measures will be undertaken by one of three independent observers to pre-agreed
protocols, before the first intervention session, and before intervention sessions on day
five, day ten and day of discharge. The questionnaires CF-38 and the Hospital Anxiety and
Depression Scale will be completed on initiation and completion of the study.
Sample size calculation: The number of patients needed for this study was based on testing
of posture before and after musculoskeletal intervention in the outpatient adult cystic
fibrosis randomised controlled trial ("Do physiotherapy musculoskeletal techniques improve
forced expiratory volume in one second (FEV1) in adults with cystic fibrosis?"; Ethics
reference number: 06/Q0404/81). To test for a three point change in thoracic index at the 5%
significance level, using a square-root of within-mean standard of error of three would
require at least 50 patients to achieve 90% power.
Analysis
Statistical advice was given by Mr Michael Roughton, Statistician, Royal Brompton Hospital
and Imperial College London. The data will be analysed using an appropriate test e.g.
t-tests or Mann-Whitney tests.
The intra & inter-rater reliability and repeatability of the measurements, by the
independent observers, will be determined using Bland Atman plots to ensure they lie within
clinically acceptable limits of agreement.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
| Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
| Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
| Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
| Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
| Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
| Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
| Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
| Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
| Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
| Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
| Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
| Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
| Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
| Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
| Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
| Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
| Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
| Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |